

## Exhibit 17

### US Short-Acting Insulin Therapies

#### AWP Cost of Therapy (\$)

*Based upon 50 unit dose*

Company/US launch	<u>Humulin R</u>	<u>Novolin R</u>
	Eli Lilly (1982)	Novo Nordisk (1991)
2003	\$534	\$557
2004	561	585
2005	606	631
2006	660	660
2007	723	723
2008	840	818
2009	890	899
2010	1,058	1,187
2011	1,428	1,436
2012	1,664	1,660
2013	1,989	1,985
2014	2,402	2,399
2015	2,810	2,794
2016	3,020	3,016
2017	3,257	3,016
2018	<b>\$3,257</b>	<b>\$3,016</b>

Source: Redbook/Truven.

**From the SDNY Whistleblower Complaint filed August 3, 2018**